A Clinical In-Use Evaluation to Assess the Tolerability and Efficacy of a Moisturizer on Acne Prone Skin

NCT07224633 | Completed

• 1 other identifier: CS2025SK100252
• Study Type: interventional
• Target: 47
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to evaluate the tolerance and efficacy of a facial moisturizer in subjects with mild to moderate acne vulgaris over a 4-week treatment period.

Conditions

Acne Vulgaris

Outcome Measures

Primary Outcomes (7)

• Investigator's assessment of efficacy

  The Investigator or the expert grader observed efficacy parameters like Visual Dryness, Tactile Surface Roughness, Lack of Radiance/Brightness, Global Fine Lines, Overall Appearance of Pores, Overall Skin Appearance, Skin Blotchiness, Uneven Skin Tone, Lack of Skin Clarity using a 10-point ordinal scale (0=none, 1-3 = mild, 4-6 = moderate, 7-9 = severe). A decrease in score compared to baseline indicates an improvement in the efficacy parameter.

  Visit 1 (Screening/Baseline: pre-product use), Visit 2 (Week 1) and Visit 3 (Week 4)

• Acne Quality of Life Index (AQOLI) 3 Domains and Group Total Scores

  Subjects will complete an Acne Quality of Life Index \[Acne-QOLI\] using a 1 to 7 scale (1 = extremely, 4 = some, 7 = not at all). A decrease in scores indicates improvement.

  Visit 1 (Screening/Baseline: pre-product use) and Visit 3 (Week 4)

• VISIA Imaging

  Full-face digital images will be taken using the site provided VISIA-CR 5 photographic imaging system.

  Visit 1 (Screening/Baseline: pre-product use) and Visit 3 (Week 4)

• Investigator's assessment of tolerability

  The Investigator will perform a clinical evaluation of each subject's neck and facial skin of Erythema, Edema, Dryness/Scaling, Rash/Irritation using a 4-point ordinal scale (0=none; 1=Mild; 2=Moderate; 3=Severe). A decrease in score compared to baseline indicates an improvement in the efficacy parameter.

  Visit 1 (Screening/Baseline: pre-product use),Visit 2(Week 1) and Visit 3 (Week 4)

• Subjects' assessment of tolerability

  The Investigator will question each subject for the parameters below regarding the subject's neck and facial skin of Burning, Stinging, Tightness/Dry Feeling , Itching , Peeling/Flaking, Overall sensitivity. Assessments will be scored on a 4-point ordinal scale (0=none; 1=Mild; 2=Moderate; 3=Severe). A decrease in score compared to baseline indicates an improvement in the efficacy parameter.

  Visit 1 (Screening/Baseline: pre-product use), Visit 2 (Week 1), and Visit 3 (Week 4)

• Subjective assessment of efficacy Part A

  Self-assessment regarding the current condition (Appearance of redness associated with pimples, Oiliness of skin, Shininess of skin, Dryness of skin, Flakiness of skin, Skin smoothness, Appearance of pores, Redness of skin, Overall appearance of skin) of facial skin using a 1-10 scale. A decrease in score indicates an improvement in the efficacy parameter.

  Visit 1 (Screening/Baseline: pre-product use), Visit 2 (Week 1) and Visit 3 (Week 4)

• Subjective assessment of efficacy Part B

  Self-assessment on efficacy at post product use timepoint. Frequency and percentage of all answers for all questions, and a binomial test (sign test) p-value will be provided for applicable questions. A higher percentage of favorable responses with a significant p-value indicates positive subject perceptions of the IP.

  Visit 1 (Post product use), Visit 2 (Week 1) and Visit 3 (Week 4)

Study Arms (1)

Experimental group: Moisturizer Use

EXPERIMENTAL

Other: Use of Barrier Building Moisturizer

Interventions

Use of Barrier Building Moisturizer OTHER

Subjects will use the facial moisturizer for 4 weeks according to the following: Apply evenly to your face and neck once daily (or twice daily, if desired) after washing your face with your regularly used facial cleanser for the duration of the study. Record all product applications in the daily diary.

Experimental group: Moisturizer Use

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Fitzpatrick Skin Type of I to VI, targeting the following:
• Skin types I, II, III, or IV: 60-70% of enrolled subjects
• Skin types V or VI: 30-40% of enrolled subjects
• Has acne as determined by PI and is undergoing current stable, daily treatment of acne for at least one month prior to study initiation.
• a. Treatments may include but are not limited to, either prescription or over-the counter products, such as: Benzoyl Peroxide, Retinoids (Adapalene, Tretinoin, Tazarotene), Topical Antibiotics and oral antibiotics (if used at least 30 days prior to Visit 1), Topical Dapsone, and Epiduo. Note: use of oral isotretinoin (Accutane) is prohibited. Targeting up to 20 subjects currently using a prescription treatment.
• Willing to continue his/her normal course of treatment (used at least 30 days prior to Visit 1), for their skin condition with no changes during the study.
• Generally, in good health based on medical history reported by the subject.
• Able to read, write, speak, and understand English
• Individuals have signed the ICD including the photo release and Health Insurance Portability and Accountability Act (HIPAA) disclosure
• Intends to complete the study and is willing and able to follow the subject responsibilities.

You may not qualify if:

• Has severely sensitive skin and/or has known allergies or adverse reactions to common topical skincare products or to ingredients in the IP or has demonstrated a previous hypersensitivity reaction to any of the ingredients in the IP.
• Has a clinically significant, unstable medical disorder(s)
• Is unwilling or unable to comply with the requirements of the protocol.
• Has a history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study.
• Has any surgery and/or invasive medical procedure planned during the course of the study.
• Has started a hormone replacement therapy (HRT) or hormonal birth control less than 3 months prior to Visit 1 or plans on starting, stopping, or changing doses of HRT or hormonal birth control during the study
• Presents with a pre-existing or dormant facial dermatologic condition that, in the PI or designee's opinion, may confound the study results or otherwise be inappropriate for study participation (e.g., severe acne, acne conglobata, psoriasis, rashes, skin cancer, many and/or severe excoriations, observable suntan, scars, nevi, tattoo, excessive hair, etc.)
• Has self-reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication.
• Is taking/using medications or a product that would mask an adverse event (AE) or influence the study results, including:
• Steroidal drugs within 2 months before Visit 1
• Non-steroidal anti-inflammatory drugs within 5 days before Visit 1
• Antihistamines within 2 weeks before Visit 1
• Oral isotretinoin (Accutane) within 6 months to Visit 1
• Anticancer and immunosuppressive treatments/medications (e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate, Remicade, Stelara) currently or within 3 months before Visit 1
• Radiation currently or within 1 week before Visit 1

Sponsors & Collaborators

• Kenvue Brands LLC: lead

Study Sites (1)

TKL Research Inc. - Fair Lawn

Fair Lawn, New Jersey, 07410, United States

Location

MeSH Terms

Conditions

Acne Vulgaris

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This is a single-center, monadic clinical study. This study is not randomized or blinded. All subjects will be testing the same IP.

Study Record Dates

• First Submitted: November 1, 2025
• First Posted: November 5, 2025
• Study Start: October 7, 2025
• Primary Completion: December 16, 2025
• Study Completion: December 16, 2025
• Last Updated: December 29, 2025

Record last verified: 2025-12-18

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)